Jamie is an investment professional on the Frazier Life Sciences team, identifying and evaluating companies advancing novel therapeutics.
Jamie joined Frazier Healthcare Partners in 2016 and focuses on investment identification, due diligence, and deal closing for development-stage biotechnology companies. He was involved in Frazier’s investments in Ignyta (acquired by Roche), ARMO (acquired by Eli Lilly), Bellicum Pharmaceuticals (NASDAQ: BLCM), Kezar Life Sciences (NASDAQ: KZR), Krystal Biotech (NASDAQ: KRYS), Sojournix and Synlogic (NASDAQ: SYBX).
Prior to joining Frazier, Jamie was a management consultant with the Boston Consulting Group, where he was a core member of the Healthcare Practice. In this capacity, he led projects involving Biotechnology mergers and acquisitions, R&D, manufacturing and business development strategy.
Jamie received his M.D. from the University of Southern California, where he was inducted into the Alpha Omega Alpha honors society, and his B.A. from Middlebury College. He completed his post-graduate training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston. He has co-authored several papers in top-tier journals on genomic instability and its role in cancer.
Middlebury College (B.A.)
University of Southern California (M.D.)